Biotech Values

[mcbio]

Not only AAG doesn't relate to specific disease but also change too often, thus the nominal increase of response rate from 22% to 32% by using AAG baseline data point as "biomarker" retrospectively reflected something else in the trial population.

I wouldn't call a 45% increase in response rate nominal. Nonetheless, I still get the caveats about AAG selection.